NCT06909565ClinicalTrials.gov
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION)
باختصار
V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin therapy and on…
المرحلة 4مطلوب 6,000 مشارك153 موقعاًدولة واحدة
الفئات
مسجَّلة في سجل واحد
- ClinicalTrials.govNCT06909565فتح هذا السجل في ClinicalTrials.govتمت المزامنة أول أمس
يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.
تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.
هل أنت مهتم بهذه الدراسة؟
تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2025-04-03; recorded start 2025-07-23
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 475 other studies in this databaseCounted from the lead sponsor named in the record (Duke University)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 2 conditions.
- Lead sponsor type recorded as: other.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A definitive-grade design for a phase 4 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm15/15
Active-comparator control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type10/10
Mortality / MACE endpoint (hard clinical outcome)
- Multi-centre8/8
Multi-centre: 115 sites
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A large study: 6,000 participants (target), run at 153 sites.
How this score is built
- Enrolment36/40
6,000 participants (target)
- Site count23/25
115 sites
- Country count0/15
Single country
- Planned duration9/10
Planned over about 53 months
- Sponsor scale10/10
Duke University has led 456 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
ملخص
V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin therapy and on the market to lower LDL-C in high-risk populations.
الحالات
- Percutaneous Coronary Intervention
- Peripheral Endovascular Intervention
الأهلية
| الجنس | الجميع |
|---|---|
| الأعمار | 18 Years – لا حد أقصى |
| المتطوعون الأصحّاء | لا |
الأهلية كما كُتبت في السجل
الأهلية في عبارات بسيطة
لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.
تصميم الدراسة
| نوع الدراسة | تدخّلية |
|---|---|
| المرحلة | المرحلة 4 |
| التخصيص | معشّاة |
| نموذج التدخّل | PARALLEL |
| الغرض الأساسي | PREVENTION |
| التعمية | QUADRUPLE (4) |
| التجنيد | مطلوب 6,000 مشارك |
الجهة الراعية والمتعاونون
- Duke University الجهة الراعية
- Novartis Pharmaceuticals المتعاونون
- Colorado Prevention Center المتعاونون
- Mount Sinai Hospital, New York المتعاونون
الأذرع والتدخلات
- Inclisiran SodiumACTIVE_COMPARATOR
Inclisiran sodium 300 mg subcutaneous injection
- PlaceboPLACEBO_COMPARATOR
Normal saline 1.5 ml subcutaneous injection
التدخلات
- دواء Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
300 mg (equivalent to 284 mg inclisiran) in 1.5 mL subcutaneous injection at Day 0; Day 90; \& every 6 months thereafter
- دواء Normal Saline (Placebo)
Normal saline placebo subcutaneous injection given at Day 0, Day 90; \& every 6 months thereafter
مقاييس النتائج
مقياس النتيجة الأولي
Total number of major adverse cardiovascular events (MACE) after coronary or peripheral endovascular revascularization
MACEs include CHD death, non-fatal MI, ischemic stroke, ALI, major (above the ankle) amputation of vascular etiology, clinically driven coronary and limb revascularization.
الإطار الزمني From randomization to first occurrence of MACE (up to approximately 4 years)
مقياس النتيجة الأولي
Total number of major adverse limb events (MALE) after endovascular revascularization
MALEs consist of ALI, major amputation of vascular etiology, clinically driven lower extremity peripheral revascularization.
الإطار الزمني From randomization to first occurrence of MALE (up to approximately 4 years)
مقياس النتيجة الثانوي
Number of participants with cardiovascular (CV) death
الإطار الزمني From randomization to CV death (up to approximately 4 years)
مقياس النتيجة الثانوي
Number of participants with all cause death
الإطار الزمني From randomization to all cause death (up to approximately 4 years)
مقياس النتيجة الثانوي
Number of participants with venous thromboembolic events (VTE)
الإطار الزمني From randomization to first VTE (up to approximately 4 years)
التواريخ
| تاريخ البدء | 23 يوليو 2025 (فعلي) |
|---|---|
| الإتمام الأولي | 1 أكتوبر 2029 (تقديري) |
| الإتمام | 1 ديسمبر 2029 (تقديري) |
| أول نشر | 3 أبريل 2025 (فعلي) |
| آخر تحديث | 16 نوفمبر 2026 |
| النتائج منشورة | غير مذكور في سجل السجل |
| آخر تأكيد للحالة | يوليو 2026 |
فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.
المواقع
149 موقعاً قيد التجنيد
United States
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Capital Cardiology Associates | Albany | New York | قيد التجنيد |
| Presbyterian Heart Group | Albuquerque | New Mexico | قيد التجنيد |
| Advanced Cardiovascular LLC | Alexander City | Alabama | قيد التجنيد |
| Amarillo Heart Clinical Research Institute, Inc. | Amarillo | Texas | قيد التجنيد |
| PharmaTex Research | Amarillo | Texas | قيد التجنيد |
| AnMed Health Medical Center | Anderson | South Carolina | قيد التجنيد |
| Asheville Cardiology Associates Research Department | Asheville | North Carolina | قيد التجنيد |
| University of Colorado Anschutz Medical Campus | Aurora | Colorado | قيد التجنيد |
| Austin Heart | Austin | Texas | قيد التجنيد |
| IMS Cardiology | Avondale | Arizona | قيد التجنيد |
| Northern Light Eastern Maine Medical Center | Bangor | Maine | قيد التجنيد |
| St. Luke's University Health Network | Bethlehem | Pennsylvania | قيد التجنيد |
| Pacific Oaks Medical Group | Beverly Hills | California | قيد التجنيد |
| Cardiology, PC | Birmingham | Alabama | قيد التجنيد |
| Grace Research, LLC | Bossier City | Louisiana | قيد التجنيد |
| Bridgeport Hospital | Bridgeport | Connecticut | قيد التجنيد |
| Advanced Heart Care LLC | Bridgewater | New Jersey | قيد التجنيد |
| Trinity Medical WNY, PC | Buffalo | New York | قيد التجنيد |
| Sisters of Charity Hospital | Buffalo | New York | قيد التجنيد |
| Capital Area Research LLC | Camp Hill | Pennsylvania | قيد التجنيد |
| Aultman Hospital | Canton | Ohio | قيد التجنيد |
| Wellspan Chambersburg Hospital | Chambersburg | Pennsylvania | قيد التجنيد |
| Mecklenburg Heart Specialists | Charlotte | North Carolina | قيد التجنيد |
| Novant Health Clinical Research/Heart & Vascular Institute | Charlotte | North Carolina | قيد التجنيد |
| Atrium Health-Sanger Heart and Vascular Institute | Charlotte | North Carolina | قيد التجنيد |
| University of Illinois Chicago | Chicago | Illinois | قيد التجنيد |
| Cardiovascular Institute of San Diego | Chula Vista | California | قيد التجنيد |
| Clearwater Cardiovascular Consultants | Clearwater | Florida | قيد التجنيد |
| BayCare Medical Group | Clearwater | Florida | قيد التجنيد |
| MedStar Southern Maryland Hospital Center | Clinton | Maryland | قيد التجنيد |
| University of Missouri Health Care | Columbia | Missouri | قيد التجنيد |
| John Muir Medical Center - Concord Campus | Concord | California | قيد التجنيد |
| Javara inc. | Conroe | Texas | مسحوب |
| Pioneer Clinical Studies | Coral Gables | Florida | قيد التجنيد |
| Valley Clinical Trials | Covina | California | مسحوب |
| Louisiana Heart Center | Covington | Louisiana | قيد التجنيد |
| Nuvance Health- Danbury Hospital | Danbury | Connecticut | قيد التجنيد |
| Cardiology Research Associates | Daytona Beach | Florida | قيد التجنيد |
| Arrow Clinical Trails | Daytona Beach | Florida | قيد التجنيد |
| Essentia Health-SMMC | Duluth | Minnesota | قيد التجنيد |
| Aspirus Saint Luke's Hospital | Duluth | Minnesota | قيد التجنيد |
| Midwest Cardiovascular Research and Education Foundation | Elkhart | Indiana | قيد التجنيد |
| Cardiovascular Associates of the Delaware Valley | Elmer | New Jersey | قيد التجنيد |
| Aurora Denver Cardiology Associates - Englewood | Englewood | Colorado | قيد التجنيد |
| Javara Inc. | Fayetteville | North Carolina | قيد التجنيد |
| Advanced Heart and Vascular Institute Of Hunterdon | Flemington | New Jersey | قيد التجنيد |
| Northeast Georgia Heart Center, PC | Gainesville | Georgia | قيد التجنيد |
| Stern Cardiovascular Center | Germantown | Tennessee | قيد التجنيد |
| Thrive Clinical Research Group | Glendora | California | قيد التجنيد |
| CHI Health Nebraska Heart | Grand Island | Nebraska | قيد التجنيد |
تُدرَج 103 مواقع إضافية في سجل السجل.
مستندات الدراسة
لا تُرتبط أي مستندات في سجل السجل هذا.
التغيّرات عبر الزمن
- 16 نوفمبر 2026
أُضيف موقع
4 sites added (153 total)
149153
- 29 أكتوبر 2026
أُضيف موقع
2 sites added (149 total)
147149
- 23 أكتوبر 2026
أُضيف موقع
2 sites added (147 total)
145147
- 19 أكتوبر 2026
أُضيف موقع
3 sites added (145 total)
142145
- 5 أكتوبر 2026
أُضيف موقع
1 site added (142 total)
141142
- 28 سبتمبر 2026
أُضيف موقع
2 sites added (141 total)
139141
- 22 سبتمبر 2026
أُضيف موقع
1 site added (139 total)
138139
- 15 سبتمبر 2026
أُضيف موقع
2 sites added (138 total)
136138
- 28 أغسطس 2026
أُضيف موقع
3 sites added (136 total)
133136
- 18 أغسطس 2026
أُضيف موقع
8 sites added (133 total)
125133
- 5 أغسطس 2026
أُضيف موقع
10 sites added (125 total)
115125